Tosano

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tosano

Property Description
Active ingredient Tranexamic Acid (C8H15NO2)
Form Oral tablet, Sterile solution for injection
Pharmacological class Antifibrinolytic agent (Hemostatic)
General purpose Prevention and control of excessive bleeding
Origin Synthetic derivative of lysine

What Type of Medicine is Tosano?

Tosano is a pharmaceutical preparation whose active ingredient is Tranexamic Acid, classified as an antifibrinolytic agent. This places it within the broader category of hemostatic medicines, intended specifically to support the body’s efforts to control bleeding.

The medication is a synthetic compound structurally related to the amino acid lysine and is manufactured as a single-ingredient product. The active substance, Tranexamic Acid, is considered a standard component for managing hemorrhage, underscoring its established role in critical care and general medicine.

Composition and General Purpose

The Tranexamic Acid in Tosano is provided in two main formats: an oral tablet and a sterile aqueous solution for injection. This dual availability allows healthcare providers to select the appropriate delivery method, either for continued management via the oral route or for rapid, systemic intervention during acute bleeding episodes.

The general purpose of Tosano is to prevent or reduce excessive blood loss by preserving the strength of blood clots. It achieves this by exerting an antifibrinolytic action that counters the natural enzymatic process (fibrinolysis) that dissolves clots. The medicine’s role is to sustain the strength of the clot, ensuring stability and supporting the body’s achievement of hemostasis.

Regulatory References

  1. affirmed as an essential medicine by the World Health Organization (WHO/NIH)

What side effects are possible with Tosano?

Adverse Reaction Summary and Safety Profile

The safety profile is based on data from clinical trials and post-marketing experience involving a compound with a structure similar to what the name suggests, which acts as a sphingosine 1-phosphate (S1P) receptor modulator. This class of medication affects the immune system by reducing the number of circulating lymphocytes in the blood, a condition known as lymphopenia. This reduction may increase the risk of infection, including common, serious, and opportunistic infections like herpes zoster.

Key Safety Considerations

Common Adverse Reactions (incidence ge 4% in trials) typically include upper respiratory tract infection, elevations in liver transaminases (hepatic enzyme increase), back pain, and hypertension (increased blood pressure).

Serious and Clinically Significant Risks require close monitoring:

  • Bradyarrhythmia and Atrioventricular Conduction Delays: The drug may cause a transient decrease in heart rate, especially upon initiation. An electrocardiogram (ECG) is recommended before starting treatment.
  • Liver Injury: Elevations in hepatic transaminases have been observed. Liver function tests are required before initiation, and treatment should be discontinued if significant liver injury is confirmed.
  • Increased Blood Pressure (Hypertension): Blood pressure should be monitored regularly throughout the course of treatment.
  • Macular Edema: A risk of fluid accumulation in the macula of the eye exists, which warrants an ophthalmic evaluation if visual changes occur.

Population-Specific Safety: The drug is generally contraindicated in patients who have experienced certain recent cardiovascular events (e.g., myocardial infarction, stroke, or severe heart failure) or who have specific pre-existing heart conduction abnormalities (e.g., Mobitz type II second-degree or third-degree atrioventricular block). Women of childbearing potential are advised to use effective contraception during treatment and for a defined period after stopping due to potential fetal risk. Lymphocyte counts typically return to the normal range within approximately one month after discontinuation.

Overdose and Emergency Response

Overdose: When to Seek Help

Overdose with this class of medication is a life-threatening medical emergency documented in official regulatory labeling. The most serious outcomes are tied to Central Nervous System (CNS) and respiratory depression, which can quickly progress to respiratory arrest and death if not treated immediately.

Documented Manifestations and Severe Outcomes

Overdose Presentation Severe Outcome Classification
Profound somnolence, stupor, coma Life-threatening risk
Shallow or slowed breathing (respiratory depression) Apnea or Respiratory Arrest
Pinpoint pupils, limp muscles Circulatory Depression, Shock

Required Emergency Actions

Immediate medical attention is required upon recognizing any signs of overdose, such as difficulty waking up, unresponsiveness, or severe breathing difficulties. Official regulatory instructions state that emergency services should be contacted without delay.

The initial management involves establishing and maintaining a clear airway and providing ventilation if needed. An opioid antagonist, such as Naloxone, is the specific antidote required for reversal. Because the antagonist's effects may wear off before the effects of the opioid, continuous observation and monitoring are essential to manage the risk of recurring respiratory depression. Accidental ingestion, especially by a child, may result in a fatal overdose, emphasizing the severity noted in government-authorized documents.

Therapeutic Uses of Tosano

Tosano is commonly used in situations involving symptoms related to excessive bleeding. The medication is used for managing conditions characterized by excessive and prolonged blood loss, such as heavy menstrual bleeding (menorrhagia), and may be part of symptomatic management during episodes of acute, critical hemorrhage following major trauma or postpartum events. It is also used in high-risk scenarios, including major surgical procedures and for patients with inherited bleeding disorders undergoing interventions like dental work.

By providing support for the body's natural blood clotting process, the medicine may assist with easing the symptom burden associated with the volume and duration of bleeding. This contributes to improved comfort during symptomatic periods.

“This medication is relevant across domains where additional symptomatic support is needed to help patients cope more steadily with difficult or disruptive bleeding episodes.”

In a specialized context, it is also considered relevant for easing the symptoms associated with the frequency and intensity of swelling attacks in individuals with Hereditary Angioedema (HAE).


Therapeutic Focus: Easing Symptoms of Excessive Bleeding

Tosano is commonly used to help with symptomatic relief in conditions presenting with significant symptomatic burden related to various forms of excessive blood loss, assisting with maintaining functional stability during challenging phases.

Eligibility and Restrictions for Use

Eligibility for Tosano (Tranexamic Acid): Official Regulatory Information

The eligibility for using Tosano is strictly defined by regulatory documents, focusing on patient safety profiles and specific contraindications. Use is generally established in adults and in children from one year of age for certain approved indications.


Absolute Contraindications

Patients must not use this medicine if they have:

  • Active thromboembolic disease (e.g., pulmonary embolism, deep vein thrombosis, or cerebral thrombosis).
  • A history of thrombosis or a high risk for blood clots.
  • Severe renal impairment, due to the risk of drug accumulation.
  • Subarachnoid hemorrhage, due to the potential risk of cerebral edema and infarction.
  • Known hypersensitivity to tranexamic acid.

Restricted and Non-Recommended Populations

Population Group Regulatory Status
Pregnancy (First Trimester) Not recommended due to insufficient data.
Lactation Not recommended, as the substance is excreted in breast milk.
Children under one year Not recommended; safety and efficacy data are limited.
Mild to Moderate Renal Impairment Restricted use; mandatory dose reduction is required.
Postmenopausal Women Not indicated for heavy menstrual bleeding.

Eligibility also restricts administration routes; for instance, the injectable form is contraindicated for intrathecal or intracerebral application.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Tosano focuses on pharmacodynamic patterns due to its classification as an antifibrinolytic agent. The most restrictive interaction classification is the formal contraindication for co-administration with combined hormonal contraceptives, as this combination significantly increases the documented risk of venous and arterial thromboembolism. Similarly, the use of Factor IX Complex Concentrates and Anti-inhibitor Coagulant Concentrates is prohibited in combination due to the potential for heightened thrombotic risk.

Other pharmacodynamic interactions exist with medical products that affect the hemostasis system. Co-administration with general prothrombotic medical products must be officially avoided. The antifibrinolytic action of Tosano is noted to be antagonised by co-administration with thrombolytic drugs, potentially reducing the medicine's effect. Simultaneous treatment with anticoagulants requires strict regulatory supervision. Furthermore, the official label notes that Tosano is not recommended for use with All-trans Retinoic Acid in patients with Acute Promyelocytic Leukemia due to a possible exacerbation of the procoagulant effect.

Regarding other types of interactions, regulatory documents confirm the absence of documented metabolic interactions via Cytochrome P450 (CYP) enzymes. There are no mandatory timing separation rules listed for co-administered substances, and the oral tablet may be taken with or without food. A population-specific constraint exists for patients with impaired renal function, where the risk of drug accumulation is greater, increasing the overall risk profile.

Mechanism of Action

Targeted Inhibition of the Fibrinolysis Pathway

The fundamental action of Tosano's active ingredient, Tranexamic Acid, is the targeted competitive inhibition of the body's natural clot-dissolving mechanism, known as fibrinolysis. The drug, acting as a synthetic lysine analog, engages the lysine-binding sites (LBSs) on the precursor enzyme plasminogen. This molecular interaction blocks plasminogen from attaching to the fibrin surface of the blood clot, directly preventing its activation into the active enzyme, plasmin. The action results in the preservation of the fibrin structure's stability and persistence.

Stabilization and Preservation of the Fibrin Clot

By interfering with the early molecular steps that activate plasminogen, the drug effectively limits the subsequent breakdown of the fibrin matrix at the site of the clot. This cascade modification ensures the physical and structural integrity of the hemostatic plug is maintained against degradation, which is the key physiological consequence of the drug's action. This mechanism only addresses clot breakdown and is functionally distinct from processes related to the initial formation of the clot (coagulation factor activation).

Off-Target Central Nervous System (CNS) Activity

At high systemic concentrations, the molecule exhibits a secondary action by antagonizing (blocking) the GABA A receptors in the CNS. This modulation of a major inhibitory neurotransmitter system leads to neuronal hyperexcitability, defining a mechanistic constraint that is functionally separate from the drug's peripheral antifibrinolytic effect.

Dosage and Administration Information

How Tosano is Used: Administration Guidelines

Tosano (Tranexamic Acid) is administered through two approved routes: the oral tablet and the sterile solution for intravenous (IV) injection or infusion. Its use is defined by technical specifications which govern dosing, frequency, duration, and method of administration.


Dosing and Schedule

Application Route Standard Dose (Adults) Frequency and Duration
Heavy Menstrual Bleeding Oral 1,300 mg (2 x 650 mg tablets) Three times daily (TID) for a maximum of 5 days during monthly menstruation
Post-Procedure Bleeding (e.g., in hemophilia) IV 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days, as short-term use

Required Administration and Special Conditions

Administration Method

  • Oral Tablets: Tablets must be swallowed whole; they should not be chewed, broken, or crushed. Dosing may be administered with or without food.
  • IV Injection: The solution must be administered very slowly. The rate of injection should generally not exceed 1 mL per minute for the 100 mg/mL concentration. The medicine must not be administered by the intramuscular route.

Physiological Adjustments

  • Renal Impairment: Dosage must be reduced in patients with renal impairment, with specific dose and frequency adjustments based on the serum creatinine concentration.
  • Hepatic Impairment: No dose adjustment is generally required.

The medicine is used in a cyclic pattern for heavy menstrual bleeding and for short-term post-procedure control, ensuring the duration of use is limited by the labeled schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tosano

Evidence for Use in Menstrual and Post-Delivery Bleeding

The research on Tosano (Tranexamic Acid) has included several Randomized Controlled Trials (RCTs) and Meta-analyses for heavy menstrual bleeding, a condition characterized by periods involving heightened symptoms. Researchers examined outcomes related to quantifying menstrual blood loss volume and monitored patient-reported outcomes describing perceived discomfort. Findings described patterns related to the measured blood loss volume when comparing the group receiving the medication to the control group. Studies report how symptoms evolved in the observed populations and findings helped contextualize how patients reported their experience.

Research has also evaluated Tosano in the context of postpartum hemorrhage (PPH). Large-scale trials were studied for their impact on severe outcomes, including maternal mortality attributed to bleeding. These studies report how symptoms evolved in the observed populations, focusing on short-term outcomes measured up to 30 days after delivery. The evidence data show patterns related to the timing of administration when evaluating specific outcome patterns observed in these settings.


Evidence for Use in Acute and Major Bleeding

Tosano was studied for its role in managing acute, critical hemorrhage, such as that resulting from major trauma. Multi-center RCTs included adults with significant, acute bleeding. Studies monitored all-cause mortality at 28 days. Findings described patterns associated with early administration (within 3 hours) when compared to placebo or later administration. The research describes patterns related to the measured need for blood transfusion when observing the group receiving Tranexamic Acid.

The medication was evaluated in research exploring its use during major surgical procedures. Studies monitored outcomes focusing on quantifying perioperative blood loss and the need for allogeneic blood transfusion. Findings were mixed regarding the magnitude of the measured changes when comparing results across the variety of surgical types and different ways the medication was observed in the studies.


What Is Still Uncertain About Tosano’s Research Base

A significant limitation across the research base is the focus on short-term outcomes for most acute conditions. Long-term effects are not fully established, and there is limited information regarding maintenance data or the durability of the observed patterns. For trauma and PPH, the evidence data show patterns related to the timing of administration. Results apply only to the populations studied under those specific time constraints.

Frequently Asked Questions (FAQ)

Common questions about Tosano (FAQ)


Q: What health problems is Tosano used to treat?

Tosano's active ingredient, Tranexamic Acid, is officially used to help control and prevent excessive bleeding. Official uses include managing heavy menstrual bleeding and addressing short-term bleeding following certain medical procedures, such as those related to hemophilia. The medicine works by preserving the stability of blood clots.


Q: What are the benefits of using Tosano over other similar treatments?

The benefit of Tosano is its antifibrinolytic mechanism; it specifically works by preventing the premature breakdown of a blood clot after it has formed. This action helps maintain the clot's integrity and structural stability, supporting the body's natural ability to stop bleeding. This unique way of working is distinct from medications that influence the initial process of clot formation.


Q: How long does it typically take for Tosano to start working?

The specific time it takes for the medication to affect the body's clotting mechanisms is not always specified in patient information. Official documentation mainly emphasizes the importance of early administration (for example, within 3 hours for major trauma) to achieve the intended clinical benefit.


Q: What are the most common side effects of Tosano?

According to clinical trials, common adverse reactions include symptoms like upper respiratory tract infection, elevations in liver enzyme levels, back pain, and increased blood pressure (hypertension). Any unexpected or severe symptoms should be brought to the attention of the prescribing healthcare professional.


Q: Are there any serious or rare side effects associated with Tosano that I should be aware of?

The official safety profile highlights the potential for serious risks, including issues with heart rhythm (bradyarrhythmia), liver injury, and fluid accumulation in the eye (macular edema). There is also a risk of thromboembolic events (blood clots), especially when taken with combined hormonal contraceptives. If any serious symptoms occur, emergency medical services should be contacted.


Q: What is the expected duration of treatment with Tosano?

The use of Tosano is for short-term management of bleeding episodes. For heavy menstrual bleeding, the maximum duration is 5 days per menstrual cycle. For other conditions like post-procedure bleeding, the treatment may last between 2 to 8 days, as defined by official prescribing information.


Q: What should I do if I miss a dose of Tosano?

Official guidance generally instructs the patient to take it as soon as it is remembered if a dose is missed. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to avoid taking too much. Patients are typically advised to never take a double dose to compensate for a missed one.


Q: Can Tosano be taken with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Official regulatory documents confirm that Tosano is not known to interact metabolically with other medicines and can be taken with or without food. However, the official label does not specifically mention common pain relievers, and it is important for a healthcare professional to review all medications being taken.


Q: Is it safe to drink alcohol while taking Tosano?

Regulatory documents do not list a specific formal prohibition against drinking alcohol while taking Tosano. If there are concerns, patients should consult their healthcare provider, as alcohol can sometimes increase the risk of certain side effects or interfere with the body's healing processes.


Q: Is Tosano safe for children to use, and what is the age limit?

Official regulatory documents state that use is established in children from one year of age for certain approved indications, such as in hemophilia. Use is generally not recommended for children under one year due to limited safety and efficacy data. The proper dosage is determined by a healthcare provider based on the child's weight and condition.


Q: Is it necessary to take Tosano with food, and why?

Tosano oral tablets may be taken with or without food, as official information indicates. Food does not typically affect the way the medicine is absorbed. The drug's effectiveness is generally maintained regardless of whether it is taken on an empty or full stomach.


Q: What happens if I stop taking Tosano too soon?

As an anti-bleeding agent, the drug is prescribed for short-term use to manage or prevent bleeding episodes. Stopping the medication earlier than prescribed by your doctor may lead to the recurrence of heavy bleeding or loss of the desired therapeutic effect.


Q: Can Tosano be used to prevent an illness, or is it only for treatment?

Tosano is generally classified as a hemostatic agent, and its general purpose is the prevention and control of excessive blood loss. Therefore, it is often used preventatively (prophylactically), such as before a surgical procedure or at the beginning of a menstrual cycle, as well as for the active treatment of a bleeding episode.


Q: Is there a generic version of Tosano available?

Yes, regulatory agencies like the FDA have approved generic versions of the active ingredient, Tranexamic Acid. These generic products are confirmed to be bioequivalent and therapeutically equivalent to the brand-name product.


Q: Why is Tosano prescribed for a short duration, usually only three days?

Tosano is a specific type of anti-bleeding agent indicated only for short-term use. This constraint is due to the drug’s intended purpose—to manage acute bleeding events—and regulatory restrictions that aim to limit the time the drug is active in the body, which helps mitigate the risk of developing blood clots (thromboembolic events).


Q: Does Tosano cause drowsiness or affect the ability to drive or operate machinery?

Official information indicates that Tosano may cause side effects such as dizziness (giddiness) and visual disturbances. The official label suggests that patients avoid operating machinery or driving until they know how the medication affects them.


Q: Is stomach pain a common complaint for people taking Tosano?

Gastrointestinal issues, including stomach pain, nausea, vomiting, and diarrhea, are common adverse reactions reported in official product labels. These effects may sometimes be managed by reducing the dose, but any persistent or severe gastrointestinal issues should be discussed with a healthcare professional.


Q: Does Tosano have any known effects on mental health or mood?

In addition to its anti-bleeding action, the drug has a secondary effect on the Central Nervous System (CNS). While rare, serious effects like convulsions and changes in mental status have been reported. If unusual changes in mental state or mood are observed, they should be reported to a healthcare provider.


Q: Why are tablets not recommended for younger children for this medication?

While use is established in children over one year, the official prescribing information notes that the dose and use must be carefully determined by a physician. The use of the medication in children under one year is generally not recommended due to a lack of sufficient safety and efficacy data in that population.


Q: Is Tosano gluten-free or suitable for people with common allergies?

Official documentation confirms that Tosano is contraindicated if a patient has a known hypersensitivity (allergic reaction) to the active substance or any of its inactive ingredients (excipients). Information regarding common ingredients like gluten or lactose is typically detailed in the full product label and should be confirmed if there are specific allergies.


Q: Does Tosano interact with anesthesia or pain medication used during surgery?

While there are generally no direct drug-drug interactions with common anesthetic agents, there is a critical regulatory warning about the injectable solution. It must never be confused with or administered via the neuraxial route (spinal or epidural injection) instead of local anesthetics, as this can lead to severe neurological injury. The administration process relies on strict verification protocols by healthcare providers to prevent errors.


Q: What is the difference between the brand name Tosano and its generic equivalent?

The primary difference is the manufacturer and the name. The active ingredient, Tranexamic Acid, is the same. Regulatory bodies have confirmed that the generic equivalent is both bioequivalent and therapeutically equivalent to the brand-name Tosano, meaning it works the same way and has the same clinical effect.

How should Tosano be stored and disposed of?

How to Store and Dispose of Tosano (Tranexamic Acid)

The official storage and disposal requirements for Tosano are strictly defined to maintain the product's stability and ensure safety. All forms of the medicine must be stored out of the sight and reach of children.


Storage Conditions

  • Oral Tablets: Store the tablets in the original package at temperatures not exceeding 30 C.
  • Sterile Solution for Injection: Store the unmixed solution at Controlled Room Temperature (20 C to 25 C) and do not refrigerate or freeze some presentations. The solution may also require protection from light.

Stability and Disposal

Diluted solutions for injection have a limited stability and must be administered or discarded after 4 hours. Any unused product or waste material, including unused portions of the sterile solution, must be disposed of in accordance with local pharmaceutical requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tosano found in:

A-Z Index: